Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
10/2005
10/18/2005CA2098834C Wet powder film-forming compositions
10/15/2005CA2738682A1 Soft gel delivery system for treating poultry
10/13/2005WO2005095621A1 Method of regulating gene introduction with use of artificial magnetic material and system therefor
10/13/2005WO2005095464A1 Hyaluronic acid/methotrexate compound
10/13/2005WO2005095460A2 Bi-specific antibodies for targeting cells involved in allergic-type reactions, compositions and uses thereof
10/13/2005WO2005095443A1 Drug delivery system using peptide modification
10/13/2005WO2005095413A1 Antitumor agent
10/13/2005WO2005095412A1 Antiallergic agent
10/13/2005WO2005094912A1 Transplantation graft with enhanced angiogenic effect
10/13/2005WO2005094898A2 Chemically modified protein compositions and methods
10/13/2005WO2005094897A2 Pegylated ion channel modulating compounds
10/13/2005WO2005094896A2 Targeted serotonin reuptake inhibitors
10/13/2005WO2005094895A1 Production and use of the methotrexate-albumin conjugate as an immunosuppressive agent in gvhd
10/13/2005WO2005094894A1 Preparation for transferring nucleic acid into cell
10/13/2005WO2005094893A2 Freeze-dried, free-flowing, particulate composition having improved palatability
10/13/2005WO2005094892A1 Nutritional product
10/13/2005WO2005094891A2 Method for solubilising peptide mixtures
10/13/2005WO2005094884A2 Boron containing nanoparticles targeted to t-cells
10/13/2005WO2005094882A1 Modified antibodies to prostate-specific membrane antigen and uses thereof
10/13/2005WO2005094881A1 Antibody drug
10/13/2005WO2005094878A1 Composition having antitumor effect
10/13/2005WO2005094842A1 Vitamin b12-containing compositions and methods of use
10/13/2005WO2005094831A1 Sustained-release tablet formulation
10/13/2005WO2005094814A1 External preparation
10/13/2005WO2005094812A1 Nateglinide-containing preparation
10/13/2005WO2005094811A1 Pharmaceutical product containing tranilast
10/13/2005WO2005094794A1 Controlled release formulation for oral administration of metformin
10/13/2005WO2005094792A1 Anionic hydrogel matrices with ph dependent modified release as drug carriers
10/13/2005WO2005094789A1 S/o type pharmaceutical preparation and process for producing the same
10/13/2005WO2005094788A1 Fine dispersion of sparingly soluble drug and process for producing the same
10/13/2005WO2005094785A2 Compositions capable of facilitating penetration across a biological barrier
10/13/2005WO2005094422A2 Angiocidin fragments and uses thereof in clinical assays for cancer and other diseases
10/13/2005WO2005094384A2 Methods and compositions for treatment of ion imbalances
10/13/2005WO2005094265A2 Self assembling activation agents targeted using active drug release
10/13/2005WO2005094234A2 Dietary supplement for treating digestive system disorders
10/13/2005WO2005048990A3 Melt blend dispersions comprising a low water solubility drug and an ethylene oxide-propylene oxide block copolymer
10/13/2005WO2005025552A3 Protein binding compounds
10/13/2005WO2004074509A3 Reversible attachment of a membrane active polymer to a polynucleotide
10/13/2005WO2003088808A3 Compositions and methods for the diagnosis and treatment of tumor
10/13/2005US20050229264 Recombinant gelatins
10/13/2005US20050228336 Electrically assisted lidocaine and epinephrine delivery device having extended shelf-stability
10/13/2005US20050228170 B7-like molecules and uses thereof
10/13/2005US20050228103 Composition comprising intercalated metal-ion sequestrants
10/13/2005US20050228048 Stable eye drops containing latanoprost as the active ingredient
10/13/2005US20050228001 Methods and compositions for treating platelet-related disorders
10/13/2005US20050227957 Therapy for oxidation stresses; complex of drug and enzyme mimetics; lipophilic cation moiety covalently bonded to glutathione peroxidase mimetic moiety is selected from the group consisting of: benzisoselenazolones, diaryl diselenides and diaryl selenides
10/13/2005US20050227924 Peyer's patch and/or M-cell targeting ligands
10/13/2005US20050227923 Stimulation of bone growth with thrombin peptide derivatives
10/13/2005US20050227916 Administering carrier molecule such as albumin conjugated to mannose-6-phosphate; particularly targeting Hepatic Stellate Cells (HSC); glomeruloscherosis, interstitial fibrosis, lung fibrosis, atherosclerosis, Crohn's disease, colitis ulcerosa, glomerulonephritis and sepsis; diagnosis
10/13/2005US20050227911 Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules
10/13/2005US20050227910 Local regional chemotherapy and radiotherapy using in situ hydrogel
10/13/2005US20050226944 Method for oxygen treatment of unsaturated carbon compounds, novel epoxy-structured material obtained by the method, apparatus for carrrying out the method and a therapeutic composition using the material
10/13/2005US20050226938 reacting mono/di/tri or polycarboxylic acids (e.g.citric acid) with chitosan to form a first solution containing a chitosan nanoparticle that is partially crosslinked to form a core( amide linkage), forming shell on such core having free amino group on the surface with acrylic acid by amidation
10/13/2005US20050226937 Use of hyaluronic acid polymers for mucosal delivery of vaccine and adjuvants
10/13/2005US20050226935 Embolization
10/13/2005US20050226934 Inclusion complexes of active compounds in acrylate (co)polymers and methods for their production
10/13/2005US20050226933 In situ forming hydrogels
10/13/2005US20050226932 Pharmaceutical formulations for itraconazole
10/13/2005US20050226931 Stabilized silver antimicrobial devices comprising a matrix comprising a polymer network and a non-gellable polysaccharide, and an active agent; wound treatment
10/13/2005US20050226926 Sustained-release tablet composition of pramipexole
10/13/2005US20050226924 Composition comprising itraconazole for oral administration
10/13/2005US20050226910 Transdermal drug delivery system
10/13/2005US20050226907 Pharmanutrient composition(s) and system(s) for individualized, responsive dosing regimens
10/13/2005US20050226906 Nutrient system for individualized responsive dosing regimens
10/13/2005US20050226903 Water-dispersible or water-soluble poloxamers provides a drug forms with good fracture strength, flexibility, and dimensional stability; counteract triglycerides brittleness; use of a medical stick for medical administration in body cavities and/or wound cavities; veterinary medicine
10/13/2005US20050226901 Dermatological composition
10/13/2005US20050226898 Compositions and methods for transdermal oxybutynin therapy
10/13/2005US20050226897 Method of protecting against coccidiosis
10/13/2005US20050226885 Cytolysis of target cells by superantigen conjugates inducing T-cell activation
10/13/2005US20050226883 Humanized antibody
10/13/2005US20050226882 Method and multicomponent conjugates for treating cancer
10/13/2005US20050226875 Uses of anti-CTLA-4 antibodies
10/13/2005US20050226859 Peg-Modified Uricase
10/13/2005US20050226843 Polymer-based compositions and conjuates of HIV entry inhibitors
10/13/2005US20050226823 Film-shaped preparations with improved chemical stability containing active substances and method for the production thereof
10/13/2005US20050226822 Oral care products containing ovomucin
10/13/2005US20050226812 Methods of therapy and diagnosis using targeting of cells that express killer cell immunoglobulin-like receptor-like proteins
10/13/2005US20050226810 Substituted porphyrin and azaporphyrin derivatives and their use in photodynamic therapy, radioimaging and MRI diagnosis
10/13/2005US20050224372 Multiple compartment bag assembly for dialysis fluid
10/13/2005DE102004014704A1 Partikelstabilisierte Emulsionen Particle-stabilized emulsions
10/13/2005DE102004014013A1 Ein Gemisch enthaltend Fettalkohole und APG-ethercarboxylat A mixture containing fatty alcohols and APG ethercarboxylate
10/13/2005CA2847454A1 Method for modification of nmda receptors through inhibition of src
10/13/2005CA2561733A1 Pegylated ion channel modulating compounds
10/13/2005CA2561732A1 Antibody drug
10/13/2005CA2561561A1 Agent eluting bioimplantable devices and polymer systems for their preparation
10/13/2005CA2561394A1 Production and use of the methotrexate-albumin conjugate as an immunosuppressive agent in gvhd
10/13/2005CA2560595A1 Multi-vitamin and mineral nutritional supplements
10/13/2005CA2560289A1 Chemically modified protein compositions and methods
10/13/2005CA2557999A1 Methods and compositions for treatment of ion imbalances
10/13/2005CA2552542A1 Controlled release pharmaceutical composition of tolperisone for oral administration
10/13/2005CA2551797A1 Anionic hydrogel matrices with ph dependent modified release as drug carriers
10/13/2005CA2539043A1 Compositions capable of facilitating penetration across a biological barrier
10/12/2005EP1583782A2 Cationic graft-copolymer for non-viral gene delivery vector
10/12/2005EP1583777A2 Methods of therapy and diagnosis using targeting of cells that express ly-9
10/12/2005EP1583772A2 Employment of rotavirus proteins, derived proteins and peptides for the modulation of tissue permeability
10/12/2005EP1583713A1 Peptide nanostructures encapsulating a foreign material and method of manufacturing same
10/12/2005EP1583562A2 Aprotinin and analogs as carriers across the blood-brain barrier
10/12/2005EP1583561A2 Tissue reactive compounds and compositions and uses thereof
10/12/2005EP1583560A1 Composition for intracellular transport of biological particles or macromolecules
10/12/2005EP1583559A1 Compositions for prevention and treatment of cold and influenza-like symptoms comprising select mucoadhesive polymers
1 ... 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 ... 1712